SCHEMBL3592244

SCHEMBL3592244

C[C@H](C(N)=O)[C@H](O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
ADRA2C P18825 2/20 0.57
LMNA P02545 2/20 0.57
ADRA2A P08913 1/20 0.57
HIF1A Q16665 1/20 0.57
ALDH1A1 P00352 3/20 0.55
ALOX5 P09917 1/20 0.53
AOC3 Q16853 3/20 0.50
GAA P10253 1/20 0.49
CHRM2 P08172 1/20 0.48
ADRA1A P35348 1/20 0.48
RGS12 O14924 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8151796 1.00 KDM4E (0.57) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL3346793 1.00 KDM4E (0.57) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL2633793 1.00 KDM4E (0.57) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL5964063 1.00 KDM4E (0.57) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL17702817 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL8209874 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL8001841 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL12265956 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL12313665 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A
SCHEMBL28229063 0.83 LMNA (0.56) KDM4EADRA2CLMNAADRA2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796696-B2 Substituted arylcyclopentenes as therapeutic agents ALLERGAN, INC. (US) 2017-10-24 US disclosed
US-20170057941-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ALLERGAN, INC. 2017-03-02 US disclosed
US-9365485-B2 Substituted arylcyclopentenes as therapeutic agents ALLERGAN, INC. (US) 2016-06-14 US disclosed
US-20140323510-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2014-10-30 US disclosed
US-8722726-B2 Substituted arylcyclopentenes as therapeutic agents ALLERGAN, INC. (US) 2014-05-13 US disclosed
US-20100137347-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2010-06-03 US disclosed
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323510-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ABCB1, THPO, UGT2B7 KDM4E 2381/4885ADRA2C 570/4885LMNA 3131/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM4E 4596/4885ADRA2C 966/4885LMNA 2373/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM4E 4540/4885ADRA2C 1092/4885LMNA 2746/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM4E 4596/4885ADRA2C 966/4885LMNA 2373/4885
US-20170057941-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ABCB1, THPO, UGT2B7 KDM4E 2381/4885ADRA2C 570/4885LMNA 3131/4885
US-20100137347-A1 SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS ABCB1, THPO, UGT2B7 KDM4E 2953/4885ADRA2C 472/4885LMNA 2522/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM4E 4596/4885ADRA2C 966/4885LMNA 2373/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR KDM4E 4596/4885ADRA2C 966/4885LMNA 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.